News articles about Foundation Medicine (NASDAQ:FMI) have trended somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Foundation Medicine earned a daily sentiment score of 0.08 on Accern’s scale. Accern also gave news stories about the company an impact score of 45.082211778467 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the media headlines that may have effected Accern’s rankings:
- Foundation Medicine and Guardant Health Agree to Resolve False Advertising Lawsuit (finance.yahoo.com)
- HIGH PROFILE: Tjuana Byrd, new president of Women’s Foundation of Arkansas (arkansasonline.com)
- 2017 Banfield Pet Hospital® Corporate Social Responsibility Report and 2017 Banfield Foundation® Impact Report Released (bizjournals.com)
- Foundation Medicine (FMI) Q4 2017 Earnings Conference Call Transcript (finance.yahoo.com)
- Foundation Medicine (FMI) PT Raised to $80.00 at Wells Fargo & Co (americanbankingnews.com)
Foundation Medicine (NASDAQ FMI) opened at $80.05 on Wednesday. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.86 and a quick ratio of 1.67. Foundation Medicine has a 12-month low of $29.90 and a 12-month high of $87.10.
A number of brokerages have recently weighed in on FMI. BidaskClub raised shares of Foundation Medicine from a “hold” rating to a “buy” rating in a research report on Wednesday, December 27th. Zacks Investment Research raised shares of Foundation Medicine from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a research report on Wednesday, December 6th. Wells Fargo & Co reiterated a “market perform” rating and issued a $80.00 price target (up from $67.00) on shares of Foundation Medicine in a research note on Thursday, March 8th. Cowen began coverage on shares of Foundation Medicine in a research note on Thursday, February 15th. They set an “outperform” rating and a $90.00 price objective on the stock. Finally, Goldman Sachs Group began coverage on shares of Foundation Medicine in a report on Monday, January 29th. They issued a “neutral” rating and a $73.00 price objective for the company. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. Foundation Medicine presently has an average rating of “Buy” and a consensus price target of $69.60.
In other news, Director Michael J. Pellini sold 37,288 shares of Foundation Medicine stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $64.55, for a total value of $2,406,940.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Robert W. Hesslein sold 1,864 shares of Foundation Medicine stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $64.00, for a total transaction of $119,296.00. The disclosure for this sale can be found here. Insiders sold 276,452 shares of company stock worth $18,699,403 over the last ninety days. Insiders own 2.70% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by BBNS and is the property of of BBNS. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/14/foundation-medicine-fmi-getting-somewhat-favorable-media-coverage-analysis-shows/1970680.html.
About Foundation Medicine
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.